Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 9/20 | 0.47 |
| ▸ | JAK1 | P23458 | 9/20 | 0.47 |
| ▸ | TYK2 | P29597 | 7/20 | 0.47 |
| ▸ | JAK3 | P52333 | 6/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.39 |
| ▸ | KDM1A | O60341 | 4/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | GHSR | Q92847 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2575954 | 0.81 | JAK2 (0.59) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL14256422 | 0.78 | CA2 (0.56) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL14280248 | 0.73 | JAK1 (0.45) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL14280211 | 0.73 | JAK1 (0.59) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL2573586 | 0.73 | JAK2 (0.64) | JAK2JAK1TYK2JAK3KDM1A | |
| SCHEMBL14256914 | 0.73 | JAK2 (0.47) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL2569549 | 0.72 | JAK2 (0.47) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL2576247 | 0.72 | JAK2 (0.80) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL2574591 | 0.71 | JAK2 (0.49) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL2573732 | 0.71 | JAK3 (0.53) | JAK2JAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008031594-A1 | BENZOXAZOLES AND OXAZOLOPYRIDINES BEING USEFUL AS JANUS KINASES INHIBITORS | NOVARTIS AG (CH) | 2008-03-20 | — | — | WO | disclosed |